Teleflex Reports Fourth Quarter and Full Year 2024 Financial Results

Core Viewpoint - Teleflex Incorporated reported strong financial results for Q4 2024, highlighting double-digit adjusted earnings per share growth and a diversified portfolio that mitigated revenue softness in certain segments [4][6]. Financial Summary - Q4 2024 net revenue was $795.4 million, a 2.8$3,047.3 million, up 2.4% year-over-year, while adjusted revenue was $3,061.1 million, reflecting a 3.1$540.8 million in revenue, a 1.4% increase; EMEA segment revenue was $161.0 million, up 5.7$93.6 million, a 5.9% increase [7][9]. - For the full year 2024, the Americas segment reported $2,066.3 million, a 1.2$618.0 million, up 5.4%; and Asia segment revenue was $363.0 million, a 4.7$160.4 million, an 18.2% increase; Surgical revenues were $121.9 million, up 11.3$84.9 million [10][36]. - For the full year 2024, the Interventional category reported $586.0 million, a 14.6$450.5 million, up 5.4%; and Vascular Access revenues reached $732.7 million, a 3.5$8.85 and $9.25, while adjusted diluted earnings per share is expected to range from$13.95 to $14.35 [12][14]. Strategic Developments - Teleflex announced plans to acquire BIOTRONIK's Vascular Intervention business, enhancing its product offerings in coronary and peripheral intervention devices [4]. - The company intends to separate into two publicly traded entities, RemainCo and NewCo, to streamline operations and enhance management focus [4]. Share Repurchase Program - An accelerated share repurchase program of$300 million is set to commence, completing the previously authorized $500 million share repurchase program [15]. Goodwill Impairment - A non-cash goodwill impairment charge of$240 million was recognized in the Interventional Urology segment due to updated revenue forecasts reflecting market challenges [16].